Exact Sciences Corporation (EXAS) attracts a new wave of investors despite economic turmoil

The closing price of Exact Sciences Corporation (NASDAQ: EXAS) was 37.89 for the day, down -1.30% from the previous closing price of $38.39. In other words, the price has decreased by $-0.50 from its previous closing price. On the day, 1316399 shares were traded. EXAS reached its highest trading level at $38.89 during the session, while it also had its lowest trading level at $37.58.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .



Our analysis of EXAS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.20 and its Current Ratio is at 2.50. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Credit Suisse on August 25, 2022, initiated with a Outperform rating and assigned the stock a target price of $55.

On June 03, 2022, Piper Sandler started tracking the stock assigning a Neutral rating and target price of $50.

Raymond James Downgraded its Strong Buy to Outperform on November 03, 2021, whereas the target price for the stock was revised from $160 to $130.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 05 when Baranick Brian sold 984 shares for $47.12 per share. The transaction valued at 46,366 led to the insider holds 4,596 shares of the business.

Zanotti Katherine S sold 4,608 shares of EXAS for $208,005 on Jul 26. The Director now owns 60,318 shares after completing the transaction at $45.14 per share. On Jul 01, another insider, Conroy Kevin T, who serves as the President and CEO of the company, sold 7 shares for $40.75 each. As a result, the insider received 285 and left with 1,167,927 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 3.60 while its Price-to-Book (P/B) ratio in mrq is 2.08.

Stock Price History:

Over the past 52 weeks, EXAS has reached a high of $107.15, while it has fallen to a 52-week low of $34.16. The 50-Day Moving Average of the stock is 42.07, while the 200-Day Moving Average is calculated to be 58.96.

Shares Statistics:

EXAS traded an average of 2.16M shares per day over the past three months and 2.06M shares per day over the past ten days. A total of 176.36M shares are outstanding, with a floating share count of 175.40M. Insiders hold about 0.80% of the company’s shares, while institutions hold 91.30% stake in the company. Shares short for EXAS as of Jul 14, 2022 were 10.74M with a Short Ratio of 4.55, compared to 10.94M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 6.10% and a Short% of Float of 6.90%.

Earnings Estimates

The firm’s stock currently is rated by 13 analysts. On average, analysts expect EPS of $-1.07 for the current quarter, with a high estimate of $-0.91 and a low estimate of $-1.18, while EPS last year was $-1.03. The consensus estimate for the next quarter is $-1.08, with high estimates of $-0.86 and low estimates of $-1.24.

Analysts are recommending an EPS of between $-3.62 and $-4.7 for the fiscal current year, implying an average EPS of $-4.27. EPS for the following year is $-3.08, with 16 analysts recommending between $-1.33 and $-4.27.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 14 analysts. It ranges from a high estimate of $505.5M to a low estimate of $487.8M. As of the current estimate, Exact Sciences Corporation’s year-ago sales were $434.82M, an estimated increase of 14.40% from the year-ago figure. For the next quarter, 15 analysts are estimating revenue of $511.16M, an increase of 12.00% less than the figure of $14.40% in the same quarter last year. There is a high estimate of $535M for the next quarter, whereas the lowest estimate is $496.3M.

A total of 18 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $2.09B, while the lowest revenue estimate was $2B, resulting in an average revenue estimate of $2.02B. In the same quarter a year ago, actual revenue was $1.77B, up 14.50% from the average estimate. Based on 18 analysts’ estimates, the company’s revenue will be $2.35B in the next fiscal year. The high estimate is $2.46B and the low estimate is $2.29B. The average revenue growth estimate for next year is up 16.20% from the average revenue estimate for this year.